Virtici LLC

Virtici LLC, a for-profit limited liability company based in Seattle, Washington, develops biomedical therapeutics and vaccines as a federal grant recipient exclusively under National Institutes of Health programs. The vendor operates entirely as a prime recipient on federal grants — no contract primes, no subcontracting footprint — and competes in Total Small Business set-asides. Virtici has received over $3 million in prior federal grants from the NIH to support work on vaccines, diagnostics, and immunological therapeutics for infectious diseases and chronic inflammatory conditions.

Virtici's customer concentration is tightly focused on a single NIH operating division. The National Institute of Allergy and Infectious Diseases (NIAID) accounts for 12 of 23 awards tracked in the award portfolio (77% coverage), with the remaining work split among the National Institute of Dental and Craniofacial Research (4 awards), the National Institute on Aging (3 awards), and smaller sub-awards within the broader HHS/NIH system. All identified awards are federal grants under CFDA programs 93.855 (Allergy and Infectious Diseases Research), 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research), and related NIH grant lines. Representative work includes a $306,500 NIAID Project Grant awarded September 2, 2026, to develop an orally administered probiotic therapy for Klebsiella pneumoniae gastrointestinal colonization and infection (performance in Washington through August 31, 2028); a $306,341 National Institute of Arthritis and Musculoskeletal and Skin Diseases Project Grant awarded August 26, 2026, to commercialize VTC-B35, a bioengineered oral probiotic for rheumatoid arthritis (performance in Seattle through July 31, 2027); and a $300,222 NIAID Phase II SBIR grant awarded August 13, 2026, to commercialize VTC-L35, an immune-modulating probiotic for rheumatoid arthritis (performance in Seattle through January 31, 2028). Earlier work includes a $599,582 Total Small Business set-aside contract from NIAID awarded January 10, 2022, for development of toll-like receptor agonists to strengthen sublingual vaccines (completed January 9, 2024), and grants addressing periodontitis treatment, frontotemporal lobar degeneration diagnostics, Neisseria gonorrhoeae vaccination, Alzheimer's disease antibody therapeutics, and idiopathic pulmonary fibrosis biologics.

Activity has remained sparse and episodic — four awards in 2022, one in 2023, two in 2024, one in 2025, and three in 2026 — with eight awards reaching completion within the next twenty-four months. The combined potential value across all 30 awards in the portfolio is $1.2 million; however, the combined dollars obligated across all awards totals $36.2 million, indicating that many grants have already drawn their full or near-full commitment. Service Contract Inventory captures only $215 thousand in invoiced amounts across three SCI records in FY2022, delivering 0.5 FTEs on a single prime contract at a government-paid rate of $196.53 per hour. This SCI footprint reflects a very small slice of Virtici's actual federal activity and is not representative of the grant-dominated award portfolio. The vendor operates as a pure prime recipient with zero subcontracting engagement across identified awards.